Maxigesic Rapid in the US (marketed as Combogesic Rapid) is now set to be distributed through Cost Plus, the public benefit organisation founded in 2022 with the backing of the US billionaire and Shark Tank star Mark Cuban.

Cost Plus was established to lower the distribution costs of medicine. Since its founding in 2022 it has grown rapidly and now stocks more than 2,300 commonly prescribed medicines. It distributes these medicines, online and through affiliated pharmacies at cost plus a 15% markup2 and its reach extends to all 50 US states.

AFT is now concentrating on this channel to market Maxigesic Rapid for the main markets in the US, while Alexso will continue to distribute the medicine for the market segments of its distribution arrangements we disclosed in 2024 and Hikma will continue to distribute the intravenous form of the medicine.

Finally, AFT continues to expand its portfolio of medicines in this market including our Liposachet range, Kiwisoothe, and Optisoothe range. These medicines are available through Amazon presently with other channels currently under negotiation.

Source: https://investors.aftpharm.com/